📣 VC round data is live. Check it out!

Creo Medical Group Valuation Multiples

Discover revenue and EBITDA valuation multiples for Creo Medical Group and similar public comparables like Daxor, Pentixapharm Holding, BATM Advanced Communications, Meditera and more.

Creo Medical Group Overview

About Creo Medical Group

Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.


Founded

2016

HQ

United Kingdom

Employees

274

Financials (LTM)

Revenue: $10M
EBITDA: ($17M)

EV

$41M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Creo Medical Group Financials

Creo Medical Group reported last 12-month revenue of $10M and negative EBITDA of ($17M).

In the same LTM period, Creo Medical Group generated $5M in gross profit, ($17M) in EBITDA losses, and had net loss of ($2M).

Revenue (LTM)


Creo Medical Group P&L

In the most recent fiscal year, Creo Medical Group reported revenue of $5M and EBITDA of ($30M).

Creo Medical Group is unprofitable as of last fiscal year, with gross margin of 48%, EBITDA margin of (557%), and net margin of (692%).

See analyst estimates for Creo Medical Group
LTMLast FY202320242025202620272028
Revenue$10M$5M$41M$5M$8M
Gross Profit$5M$3M$21M$3M$4M
Gross Margin51%48%50%48%47%
EBITDA($17M)($30M)($28M)($35M)($19M)
EBITDA Margin(174%)(557%)(67%)(653%)(242%)
EBIT Margin(174%)(676%)(81%)(720%)(243%)
Net Profit($2M)($37M)($29M)($39M)$8M
Net Margin(25%)(692%)(70%)(718%)93%

Financial data powered by Morningstar, Inc.

Creo Medical Group Stock Performance

Creo Medical Group has current market cap of $63M, and enterprise value of $41M.

Market Cap Evolution


Creo Medical Group's stock price is $0.15.

Creo Medical Group share price decreased by 12.9% in the last 30 days, and by 23.8% in the last year.

Creo Medical Group has an EPS (earnings per share) of $-0.09.

See more trading valuation data for Creo Medical Group
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$41M$63M-0.0%-12.9%-25.6%-23.8%$-0.09

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Creo Medical Group Valuation Multiples

Creo Medical Group trades at 4.2x EV/Revenue multiple, and (2.4x) EV/EBITDA.

See NTM and 2027E valuation multiples for Creo Medical Group

EV / Revenue (LTM)


Creo Medical Group Financial Valuation Multiples

As of May 23, 2026, Creo Medical Group has market cap of $63M and EV of $41M.

Creo Medical Group has a P/E ratio of (25.4x).

LTMLast FY202320242025202620272028
EV/Revenue4.2x7.7x1.0x7.7x5.1x
EV/EBITDA(2.4x)(1.4x)(1.5x)(1.2x)(2.1x)
EV/EBIT(2.4x)(1.1x)(1.2x)(1.1x)(2.1x)
EV/Gross Profit8.2x16.1x2.0x16.1x10.9x
P/E(25.4x)(1.7x)(2.2x)(1.6x)8.4x
EV/FCF(1.4x)(1.3x)(1.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Creo Medical Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Creo Medical Group Margins & Growth Rates

Creo Medical Group grew revenue by 50% but EBITDA decreased by 35% in the last fiscal year.

In the most recent fiscal year, Creo Medical Group reported gross margin of 48%, EBITDA margin of (557%), and net margin of (692%).

See estimated margins and future growth rates for Creo Medical Group

Creo Medical Group Margins

Last FY202420252026202720282029
Gross Margin48%48%47%55%
EBITDA Margin(557%)(653%)(242%)(106%)
EBIT Margin(676%)(720%)(243%)(106%)
Net Margin(692%)(718%)93%(143%)
FCF Margin(565%)(565%)

Creo Medical Group Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth50%(87%)50%56%
Gross Profit Growth47%(88%)47%84%
EBITDA Growth(35%)26%(44%)(31%)
EBIT Growth(46%)16%(49%)(32%)
Net Profit Growth(120%)32%(120%)(339%)
FCF Growth(3%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Creo Medical Group Operational KPIs

Creo Medical Group's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.

Creo Medical Group's Rule of 40 is (51%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Creo Medical Group's Rule of X is 33% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Creo Medical Group
LTMLast FY202320242025202620272028
Rule of 40(115%)(51%)
Bessemer Rule of X(27%)33%
Revenue per Employee$0.0M
Opex per Employee$0.2M
G&A Expenses to Revenue317%758%131%758%402%
R&D Expenses to Revenue28%163%163%33%
Opex to Revenue768%130%768%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Creo Medical Group Competitors

Creo Medical Group competitors include Daxor, Pentixapharm Holding, BATM Advanced Communications, Meditera, Klea, Pulmonx, Cyclopharm, Bactiguard, Tobii and Xtant Medical.

Most Creo Medical Group public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Daxor6.1x7.2x
Pentixapharm Holding524.9x(3.1x)
BATM Advanced Communications0.4x0.5x2.6x3.9x
Meditera0.8x11.3x
Klea3.4x14.9x
Pulmonx0.7x0.7x(1.7x)(1.8x)
Cyclopharm2.9x2.8x(5.8x)(5.7x)
Bactiguard3.0x3.1x15.1x18.5x

This data is available for Pro users. Sign up to see all Creo Medical Group competitors and their valuation data.

Start Free Trial

Creo Medical Group Funding History

Before going public, Creo Medical Group raised $14M in total equity funding, across 2 rounds.


Creo Medical Group Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Sep-15Series AACF Investors; Development Bank of Wales; Pentax Medical$9MCreo Medical is a UK-based medical device company developing minimally invasive electrosurgical technology. The company developed the Croma electrosurgical platform, which combines bipolar radiofrequency and microwave energy to enable cutting and coagulation through endoscopic and single-use surgical devices for applications in therapeutic gastroenterology, laparoscopic surgery, and interventional cancer treatment. In 2015, Creo Medical completed an $8.45 million (£5.5 million) financing round led by strategic investor Pentax Medical, a subsidiary of Japanese conglomerate Hoya Corporation, with participation from existing investors Development Bank of Wales and ACF Investors. Pentax Medical's investment was driven by the company's strategy to expand into endoscopic therapy devices, complementing its existing flexible endoscopes portfolio. By the time of this round, Creo Medical had secured total funding of $20.7 million and was focused on obtaining U.S. regulatory approval for its products while building its intellectual property portfolio and pursuing commercial traction in global markets.
Nov-14Series AACF Investors; Development Bank of Wales$6MCreo Medical, a Chepstow-based developer of innovative medical devices since 2009, completed a £3.5 million second funding round on November 25, 2014, led by Finance Wales and angel investors with participation from the government-backed Angel CoFund. Existing investors including Finance Wales, the Arete Angel syndicate, and individual business angels such as lead angel Mark Farmer also joined, bringing total investment to date to £7.9 million. This marked the second co-investment deal between the Angel CoFund and Finance Wales that year. The funding supported continued development of the CROMA platform, described as the first new electrosurgical system in a generation, focusing on regulatory approval for the European market and establishing a pathway into the US market. The platform targets clinical solutions for complex gastrointestinal problems and has potential in other surgical procedures. CEO Craig Gulliford highlighted support from experienced angel investors in medical and life sciences. Development Bank of Wales (formerly Finance Wales) continued supporting Creo Medical through multiple rounds leading to its successful IPO on AIM in 2016.

Creo Medical Group M&A Activity

Creo Medical Group has acquired 2 companies to date.

Last acquisition by Creo Medical Group was on November 3rd 2020. Creo Medical Group acquired Boucart Medical for $5M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Creo Medical Group

Boucart Medical
Albyn Medical
Description
Boucart Medical is a Ghent-based distributor of gastrointestinal medical devices to hospitals in Belgium and Luxembourg. Founded in 1991, the company represents 30 international suppliers including Cook Medical and Boston Scientific, providing endoscopes, stents, and biopsy tools for endoscopy suites. It supports over 50 hospitals with training programs and inventory management, ensuring compliance with EU MDR regulations.
Albyn Medical is a Dingwall-headquartered manufacturer of single-use devices for urology, gynecology, and endoscopy procedures. Products include catheters, stone retrieval baskets, and insufflation tubing supplied to hospitals across Europe and the US. As part of Laborie, it produces in ISO-certified facilities and distributes through subsidiaries in France and Spain.
HQ CountryBelgiumUnited Kingdom
HQ City
Brussels
Inverness
Deal Date3 Nov 202029 Jul 2020
Valuation$5M$27M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Creo Medical Group acquisitions and their M&A valuation multiples.

Start Free Trial

Creo Medical Group Investment Activity

Creo Medical Group has invested in 1 company to date.

Latest investment by Creo Medical Group was on October 4th 2021. Creo Medical Group invested in IQ Endoscopes in their $6M Series A round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by Creo Medical Group

IQ Endoscopes
IQ Endoscopes
Description
IQ Endoscopes is a product line of single-use flexible endoscopes from Intelligent Endoscopy for gastrointestinal imaging. These devices capture full-length gut visuals during diagnostic and therapeutic procedures, reducing cross-infection risks compared to reusable scopes. Distributed in Europe and beyond, the range includes models for upper and lower GI tracts compatible with standard video processors.
IQ Endoscopes is a product line of single-use flexible endoscopes from Intelligent Endoscopy for gastrointestinal imaging. These devices capture full-length gut visuals during diagnostic and therapeutic procedures, reducing cross-infection risks compared to reusable scopes. Distributed in Europe and beyond, the range includes models for upper and lower GI tracts compatible with standard video processors.
HQ CountryUnited StatesUnited States
HQ City
Deal Date4 Oct 202122 Dec 2020
RoundSeries ASeed
Raised$6M$2M
InvestorsAustralian Unity; Creo Medical Group; Development Bank of Wales; Nepcoe Capital PartnersCreo Medical Group; Development Bank of Wales
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Creo Medical Group investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Creo Medical Group

When was Creo Medical Group founded?Creo Medical Group was founded in 2016.
Where is Creo Medical Group headquartered?Creo Medical Group is headquartered in United Kingdom.
How many employees does Creo Medical Group have?As of today, Creo Medical Group has over 274 employees.
Who is the CEO of Creo Medical Group?Creo Medical Group's CEO is Craig Jonathan Gulliford.
Is Creo Medical Group publicly listed?Yes, Creo Medical Group is a public company listed on London Stock Exchange.
What is the stock symbol of Creo Medical Group?Creo Medical Group trades under CREO ticker.
When did Creo Medical Group go public?Creo Medical Group went public in 2016.
Who are competitors of Creo Medical Group?Creo Medical Group main competitors include Daxor, Pentixapharm Holding, BATM Advanced Communications, Meditera, Klea, Pulmonx, Cyclopharm, Bactiguard, Tobii, Xtant Medical.
What is the current market cap of Creo Medical Group?Creo Medical Group's current market cap is $63M.
What is the current revenue of Creo Medical Group?Creo Medical Group's last 12 months revenue is $10M.
What is the current revenue growth of Creo Medical Group?Creo Medical Group revenue growth (NTM/LTM) is 59%.
What is the current EV/Revenue multiple of Creo Medical Group?Current revenue multiple of Creo Medical Group is 4.2x.
Is Creo Medical Group profitable?No, Creo Medical Group is not profitable.
What is the current EBITDA of Creo Medical Group?Creo Medical Group has negative EBITDA and is not profitable.
What is Creo Medical Group's EBITDA margin?Creo Medical Group's last 12 months EBITDA margin is (174%).
What is the current EV/EBITDA multiple of Creo Medical Group?Current EBITDA multiple of Creo Medical Group is (2.4x).
How many companies Creo Medical Group has acquired to date?As of May 2026, Creo Medical Group has acquired 2 companies.
What was the largest acquisition by Creo Medical Group?$27M acquisition of Albyn Medical on 29th July 2020 was the largest M&A Creo Medical Group has done to date.
What companies Creo Medical Group acquired?Creo Medical Group acquired Albyn Medical and Boucart Medical.
In how many companies Creo Medical Group has invested to date?As of May 2026, Creo Medical Group has invested in 1 company.
What was the last Creo Medical Group investment?On 4th October 2021 Creo Medical Group invested in IQ Endoscopes, participating in a $6M Series A round, alongside Australian Unity, Development Bank of Wales, and Nepcoe Capital Partners.
In what companies Creo Medical Group invested in?Creo Medical Group invested in IQ Endoscopes.

See public comps similar to Creo Medical Group

Lists including Creo Medical Group

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial